Form 4: Kronos Bio Director, Roger D. Dansey, Acquires 34,000 Stock Options

Director Roger D. Dansey acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.

Summary

• On June 25, 2024, Roger D. Dansey, a director of Kronos Bio, Inc., acquired 34,000 stock options.
• The exercise price of these options is $0.95.
• The options vest upon the earlier of the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.
• The options expire on June 24, 2034.
• Following the transaction, Dansey directly owns 34,000 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine insider transaction filing, neither particularly positive nor negative. It simply reflects the granting of stock options to a director.

Future Outlook

The vesting of the options is contingent upon the earlier of the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.

Industry Context

This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders.

Key Dates